EU General Court backs Lundbeck fine in pay-for-delay case

The EU General Court has backed the European Commission’s decision to fine pharma company Lundbeck and a number of generic producers.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Lundbeck and Takeda take on Lupin over anti-depressant ANDA

23 May 2018 Pharmaceutical companies Lundbeck and Takeda have sued generic drug producer Lupin for infringing a patent directed to anti-depressant medication Trintellix (vortioxetine hydrobromide).

Europe

Lundbeck loses €150m pay-for-delay appeal

30 March 2021 Lundbeck has lost an appeal to the Court of Justice of the European Union (CJEU) to waive €150 million ($176 million) in fines levied against itself and a group of five generics manufacturers over ‘pay-for-delay’ deals for its antidepressant generics.

More on this story

Americas

Lundbeck and Takeda take on Lupin over anti-depressant ANDA

23 May 2018 Pharmaceutical companies Lundbeck and Takeda have sued generic drug producer Lupin for infringing a patent directed to anti-depressant medication Trintellix (vortioxetine hydrobromide).

Europe

Lundbeck loses €150m pay-for-delay appeal

More on this story

Americas

Lundbeck and Takeda take on Lupin over anti-depressant ANDA

23 May 2018 Pharmaceutical companies Lundbeck and Takeda have sued generic drug producer Lupin for infringing a patent directed to anti-depressant medication Trintellix (vortioxetine hydrobromide).

Europe

Lundbeck loses €150m pay-for-delay appeal